KR102289767B1 - 가변적 엣지 기하학적 구조를 구비한 상처 또는 피부 치료 장치 - Google Patents
가변적 엣지 기하학적 구조를 구비한 상처 또는 피부 치료 장치 Download PDFInfo
- Publication number
- KR102289767B1 KR102289767B1 KR1020157029374A KR20157029374A KR102289767B1 KR 102289767 B1 KR102289767 B1 KR 102289767B1 KR 1020157029374 A KR1020157029374 A KR 1020157029374A KR 20157029374 A KR20157029374 A KR 20157029374A KR 102289767 B1 KR102289767 B1 KR 102289767B1
- Authority
- KR
- South Korea
- Prior art keywords
- dressing
- edge
- skin
- peak
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 claims abstract description 62
- 238000000926 separation method Methods 0.000 claims description 18
- 230000003750 conditioning effect Effects 0.000 claims description 7
- 230000002146 bilateral effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 abstract description 37
- 231100000241 scar Toxicity 0.000 abstract description 33
- 208000032544 Cicatrix Diseases 0.000 abstract description 24
- 230000037387 scars Effects 0.000 abstract description 24
- 208000002260 Keloid Diseases 0.000 abstract description 16
- 210000001117 keloid Anatomy 0.000 abstract description 16
- 230000029663 wound healing Effects 0.000 abstract description 11
- 230000002265 prevention Effects 0.000 abstract description 8
- 210000003491 skin Anatomy 0.000 description 246
- 239000000853 adhesive Substances 0.000 description 165
- 230000001070 adhesive effect Effects 0.000 description 165
- 208000027418 Wounds and injury Diseases 0.000 description 110
- 206010052428 Wound Diseases 0.000 description 104
- 230000035882 stress Effects 0.000 description 104
- 239000000463 material Substances 0.000 description 100
- 210000001519 tissue Anatomy 0.000 description 42
- 210000003739 neck Anatomy 0.000 description 35
- 239000010410 layer Substances 0.000 description 33
- 230000007246 mechanism Effects 0.000 description 29
- 239000012790 adhesive layer Substances 0.000 description 28
- 238000005452 bending Methods 0.000 description 23
- 239000013013 elastic material Substances 0.000 description 23
- 239000000758 substrate Substances 0.000 description 23
- 229920001296 polysiloxane Polymers 0.000 description 20
- 238000005520 cutting process Methods 0.000 description 18
- 210000003128 head Anatomy 0.000 description 18
- 229920001684 low density polyethylene Polymers 0.000 description 17
- 239000004702 low-density polyethylene Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000001969 hypertrophic effect Effects 0.000 description 14
- 230000037390 scarring Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 10
- 239000003522 acrylic cement Substances 0.000 description 10
- 238000007906 compression Methods 0.000 description 10
- 230000006835 compression Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 8
- -1 antifungals Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 230000035752 proliferative phase Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000002390 adhesive tape Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 229920001971 elastomer Polymers 0.000 description 7
- 229920002635 polyurethane Polymers 0.000 description 7
- 239000004814 polyurethane Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 230000037311 normal skin Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000005060 rubber Substances 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000005304 joining Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 230000036573 scar formation Effects 0.000 description 5
- 229920002725 thermoplastic elastomer Polymers 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 238000000418 atomic force spectrum Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000007493 shaping process Methods 0.000 description 4
- 239000013464 silicone adhesive Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 206010048031 Wound dehiscence Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000746 body region Anatomy 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004049 embossing Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000011379 keloid formation Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036558 skin tension Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229920003051 synthetic elastomer Polymers 0.000 description 3
- 239000005061 synthetic rubber Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 229920002799 BoPET Polymers 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 206010023330 Keloid scar Diseases 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 229940010048 aluminum sulfate Drugs 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000504 antifibrinolytic agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000009894 physiological stress Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 108010046630 polymyxin B drug combination bacitracin Proteins 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940103255 polysporin Drugs 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229940050271 potassium alum Drugs 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 229960001516 silver nitrate Drugs 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000007655 standard test method Methods 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 2
- 229950009819 zotarolimus Drugs 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920006169 Perfluoroelastomer Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 239000002783 friction material Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00582—Properties of backing
- A61F2013/006—Elastic modulus
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/844,019 US9241835B2 (en) | 2007-08-03 | 2013-03-15 | Wound or skin treatment devices with variable edge geometries |
| US13/844,154 US9668922B2 (en) | 2007-08-03 | 2013-03-15 | Wound or skin treatment devices with variable edge geometries |
| US13/844,019 | 2013-03-15 | ||
| US13/844,154 | 2013-03-15 | ||
| PCT/US2014/025084 WO2014151143A1 (en) | 2013-03-15 | 2014-03-12 | Wound or skin treatment devices with variable edge geometries |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150130527A KR20150130527A (ko) | 2015-11-23 |
| KR102289767B1 true KR102289767B1 (ko) | 2021-08-17 |
Family
ID=51580897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157029374A Active KR102289767B1 (ko) | 2013-03-15 | 2014-03-12 | 가변적 엣지 기하학적 구조를 구비한 상처 또는 피부 치료 장치 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2968017B1 (enExample) |
| JP (1) | JP6375363B2 (enExample) |
| KR (1) | KR102289767B1 (enExample) |
| CN (1) | CN105246439B (enExample) |
| BR (1) | BR112015023416B1 (enExample) |
| CA (1) | CA2905832C (enExample) |
| WO (1) | WO2014151143A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701519SA (en) | 2014-04-29 | 2017-03-30 | Roffe Medical Holdings Pty Ltd | Tissue closing method and apparatus |
| KR102505842B1 (ko) * | 2016-12-30 | 2023-03-03 | 유로메드 인코포레이티드 | 개선된 이형 라이너 시스템을 함유하는 접착 패치 |
| ES2791500T3 (es) * | 2017-05-15 | 2020-11-04 | Starsprings Ab | Disposición de colchón, tal como una cama, que tiene firmeza ajustable |
| US11730631B2 (en) | 2017-10-27 | 2023-08-22 | Kci Licensing, Inc. | Contoured foam dressing shaped for providing negative pressure to incisions in the breast |
| JP2022520048A (ja) * | 2019-02-07 | 2022-03-28 | ケーシーアイ ライセンシング インコーポレイテッド | 肩の切開に陰圧を提供するように成形された輪郭のある発泡体ドレッシング |
| EP3972525B1 (en) * | 2019-05-23 | 2025-06-25 | Leone S.p.A. | Orthodontic expander |
| AU2020400049A1 (en) * | 2019-12-10 | 2022-07-14 | Neodyne Biosciences, Inc. | Injection and infusion site treatment devices and methods |
| CN116392320B (zh) * | 2023-05-25 | 2023-11-10 | 宁波市福善印务有限公司 | 一种不干胶贴及其加工方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004121411A (ja) * | 2002-09-30 | 2004-04-22 | Kobayashi Pharmaceut Co Ltd | 皮膚貼付治療体 |
| US20070060892A1 (en) | 2005-09-09 | 2007-03-15 | Tri-State Hospital Supply Corporation | PIV dressing assembly |
| JP2010179027A (ja) | 2009-02-09 | 2010-08-19 | Dhc Co | 首用貼付材 |
| WO2012094648A1 (en) * | 2011-01-07 | 2012-07-12 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6344033Y2 (enExample) * | 1985-03-28 | 1988-11-16 | ||
| GB8629076D0 (en) * | 1986-12-04 | 1987-01-14 | Smith & Nephew Ass | Adhesive products |
| CN2192311Y (zh) * | 1994-06-13 | 1995-03-22 | 张崇玖 | 药物贴片 |
| DE19652269C2 (de) * | 1996-12-16 | 2002-04-11 | Lohmann Therapie Syst Lts | Konturen -TTS |
| US6329564B1 (en) * | 1999-11-29 | 2001-12-11 | Michael Lebner | Bandage for wound or incision closure |
| US20060037091A1 (en) | 2004-05-24 | 2006-02-16 | Gurtner Geoffrey C | Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring |
| EP1669001A1 (en) * | 2004-12-10 | 2006-06-14 | 3M Innovative Properties Company | Strip of male fastening means, patch cut therefrom, and fastening tape tab comprising such patch |
| KR101419730B1 (ko) * | 2006-08-03 | 2014-07-15 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 반흔 및/또는 켈로이드의 치료 또는 예방을 위한 디바이스 및 붕대와 그것을 위한 방법 및 키트 |
| DE602007010434D1 (de) * | 2007-06-01 | 2010-12-23 | Allergan Inc | Gerät zur Erzeugung des zugspannungsinduzierten Wachstums von biologischem Gewebe |
| EP2158888A1 (en) * | 2008-09-01 | 2010-03-03 | 3M Innovative Properties Company | Activatable precursor of a composite laminate web and elastic composite laminate web |
| CN201473484U (zh) * | 2009-08-11 | 2010-05-19 | 康晓琴 | 疤痕装饰粘胶带 |
| CN201624882U (zh) * | 2010-01-30 | 2010-11-10 | 鹤山市舒柏雅无纺布制品厂 | 一种敷颈膜 |
| CN101828939B (zh) * | 2010-06-02 | 2011-12-21 | 张升平 | 皮肤伤口锁合器 |
| JP6262531B2 (ja) * | 2010-12-29 | 2018-01-17 | スリーエム イノベイティブ プロパティズ カンパニー | 弾性ストリップ |
| US20120226214A1 (en) * | 2011-03-03 | 2012-09-06 | Neodyne Biosciences, Inc. | Devices and methods for skin tightening |
| CN203389009U (zh) * | 2013-07-31 | 2014-01-15 | 河南科技大学第一附属医院 | 一种易撕医用胶带 |
-
2014
- 2014-03-12 KR KR1020157029374A patent/KR102289767B1/ko active Active
- 2014-03-12 JP JP2016501738A patent/JP6375363B2/ja active Active
- 2014-03-12 BR BR112015023416-0A patent/BR112015023416B1/pt active IP Right Grant
- 2014-03-12 EP EP14767700.9A patent/EP2968017B1/en active Active
- 2014-03-12 CN CN201480027031.4A patent/CN105246439B/zh active Active
- 2014-03-12 WO PCT/US2014/025084 patent/WO2014151143A1/en not_active Ceased
- 2014-03-12 CA CA2905832A patent/CA2905832C/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004121411A (ja) * | 2002-09-30 | 2004-04-22 | Kobayashi Pharmaceut Co Ltd | 皮膚貼付治療体 |
| US20070060892A1 (en) | 2005-09-09 | 2007-03-15 | Tri-State Hospital Supply Corporation | PIV dressing assembly |
| JP2010179027A (ja) | 2009-02-09 | 2010-08-19 | Dhc Co | 首用貼付材 |
| WO2012094648A1 (en) * | 2011-01-07 | 2012-07-12 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2905832C (en) | 2021-09-07 |
| EP2968017B1 (en) | 2019-04-24 |
| KR20150130527A (ko) | 2015-11-23 |
| BR112015023416A8 (pt) | 2019-12-03 |
| CN105246439B (zh) | 2021-11-19 |
| HK1219865A1 (zh) | 2017-04-21 |
| CA2905832A1 (en) | 2014-09-25 |
| BR112015023416A2 (pt) | 2017-07-18 |
| CN105246439A (zh) | 2016-01-13 |
| EP2968017A1 (en) | 2016-01-20 |
| EP2968017A4 (en) | 2016-10-19 |
| JP6375363B2 (ja) | 2018-08-15 |
| BR112015023416B1 (pt) | 2021-10-13 |
| WO2014151143A1 (en) | 2014-09-25 |
| JP2016513536A (ja) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11013638B2 (en) | Wound or skin treatment devices and methods | |
| KR102289767B1 (ko) | 가변적 엣지 기하학적 구조를 구비한 상처 또는 피부 치료 장치 | |
| US9241835B2 (en) | Wound or skin treatment devices with variable edge geometries | |
| US9668922B2 (en) | Wound or skin treatment devices with variable edge geometries | |
| US20190358100A1 (en) | Radially tensioned wound or skin treatment devices and methods | |
| JP7597813B2 (ja) | 注射および注入部位治療デバイスおよび方法 | |
| KR20140122756A (ko) | 방사상으로 인장되는 상처 또는 피부 치료 장치 및 방법 | |
| HK1219865B (zh) | 具有可变边缘几何形状的伤口或皮肤处理装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151014 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190306 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200729 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20210524 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210809 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210810 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240627 Start annual number: 4 End annual number: 4 |